Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]

X
Trial Profile

TH v THL: A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2-positive metastatic breast cancer [TH versus THL]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TH v THL
  • Most Recent Events

    • 17 May 2023 This trial has been completed in Ireland, Germany, Finland, Italy and suspended in Portugal and Spain, no longer in GB according to European Clinical Trials Database record.
    • 05 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top